Close Menu
TechBrunchTechBrunch
  • Home
  • AI
  • Apps
  • Crypto
  • Security
  • Startups
  • TechCrunch
  • Venture

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Humanity appoints national security experts to governing trusts

June 6, 2025

Italian lawmakers say Italy used spyware to target immigrant activists' mobile phones, but not for journalists

June 6, 2025

Trump Mask feud was perfect for X and jumped on the app store chart

June 6, 2025
Facebook X (Twitter) Instagram
TechBrunchTechBrunch
  • Home
  • AI

    OpenAI seeks to extend human lifespans with the help of longevity startups

    January 17, 2025

    Farewell to the $200 million woolly mammoth and TikTok

    January 17, 2025

    Nord Security founder launches Nexos.ai to help enterprises move AI projects from pilot to production

    January 17, 2025

    Data proves it remains difficult for startups to raise capital, even though VCs invested $75 billion in the fourth quarter

    January 16, 2025

    Apple suspends AI notification summaries for news after generating false alerts

    January 16, 2025
  • Apps

    Trump Mask feud was perfect for X and jumped on the app store chart

    June 6, 2025

    iOS 19: All the rumor changes that Apple could bring to the new operating system

    June 6, 2025

    WWDC 2025: What to expect from this year's meeting

    June 6, 2025

    The court denied requests to suspend awards regarding Apple's App Store payment fees

    June 6, 2025

    Perplexity received 780 million questions last month, the CEO says

    June 5, 2025
  • Crypto

    xNotify Polymarket as partner in the official forecast market

    June 6, 2025

    Circle IPOs are giving hope to more startups waiting to be published to more startups

    June 5, 2025

    GameStop bought $500 million in Bitcoin

    May 28, 2025

    Vote for the session you want to watch in 2025

    May 26, 2025

    Save $900 + 90% from 2 tickets to destroy 2025 in the last 24 hours

    May 25, 2025
  • Security

    Humanity appoints national security experts to governing trusts

    June 6, 2025

    Italian lawmakers say Italy used spyware to target immigrant activists' mobile phones, but not for journalists

    June 6, 2025

    Humanity unveils custom AI models for US national security customers

    June 5, 2025

    Unlock phone company Cellebrite to acquire mobile testing startup Corellium for $170 million

    June 5, 2025

    Ransomware Gangs claim responsibility for Kettering Health Hack

    June 4, 2025
  • Startups

    7 days left: Founders and VCs save over $300 on all stage passes

    March 24, 2025

    AI chip startup Furiosaai reportedly rejecting $800 million acquisition offer from Meta

    March 24, 2025

    20 Hottest Open Source Startups of 2024

    March 22, 2025

    Andrill may build a weapons factory in the UK

    March 21, 2025

    Startup Weekly: Wiz bets paid off at M&A Rich Week

    March 21, 2025
  • TechCrunch

    OpenSea takes a long-term view with a focus on UX despite NFT sales remaining low

    February 8, 2024

    AI will save software companies' growth dreams

    February 8, 2024

    B2B and B2C are not about who buys, but how you sell

    February 5, 2024

    It's time for venture capital to break away from fast fashion

    February 3, 2024

    a16z's Chris Dixon believes it's time to focus on blockchain use cases rather than speculation

    February 2, 2024
  • Venture

    Startup Battlefield 200: Only 3 days left

    June 6, 2025

    Book all TC Stage Exhibitor Tables before ending today

    June 6, 2025

    Less than 48 hours left until display at TC at all stages

    June 5, 2025

    TC Session: AI will be on sale today at Berkeley

    June 5, 2025

    North America accounts for the majority of AI VC investment despite the harsh political environment

    June 5, 2025
TechBrunchTechBrunch

Why Theriva Biologics (TOVX) Stock Price is Poised to Rise

TechBrunchBy TechBrunchMay 23, 20243 Mins Read
Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
WHITE OAK, MD - JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)
Share
Facebook Twitter LinkedIn Pinterest Telegram Email

TLDR: Theriva Biologics (TOVX) is set for a potential stock surge due to the FDA granting Fast Track Designation to its lead candidate, VCN-01, for metastatic pancreatic cancer. This designation accelerates development and review, bolstering the drug’s market potential. With a promising pipeline and strategic positioning, TOVX is poised for significant gains.

Theriva Biologics, Inc. (NYSE American: TOVX) has recently garnered significant attention in the biotech investment community following the U.S. Food and Drug Administration’s (FDA) decision to grant Fast Track Designation (FTD) to its lead clinical candidate, VCN-01, for the treatment of metastatic pancreatic cancer. This development is a pivotal milestone that could drive the stock price higher. Let’s explore the reasons why TOVX is set for a potential surge.

Fast Track Designation: A Game-Changer

The FDA’s Fast Track Designation is designed to expedite the development and review process of drugs that address serious conditions and fulfill an unmet medical need. For Theriva Biologics, this means that VCN-01 will benefit from early and frequent interactions with the FDA during its clinical development. Additionally, the FDA may review portions of the marketing application before the complete submission, potentially accelerating the approval process.

VCN-01: Promising Clinical Candidate

VCN-01 is an oncolytic adenovirus engineered to replicate selectively within tumor cells, thereby degrading the tumor stroma that acts as a barrier to treatment. This enhances the effectiveness of co-administered chemotherapy products and promotes a robust anti-tumor immune response. In the ongoing multinational Phase 2b VIRAGE trial, VCN-01 is being tested in combination with standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) for metastatic pancreatic adenocarcinoma (PDAC).

Key Highlights of VCN-01:

• Multiple Modes of Action: VCN-01 selectively lyses tumor cells, improves chemotherapy access, and enhances tumor immunogenicity.

• Broad Clinical Application: It has been tested in over 80 patients across various cancers, showing promising results.

• Potential Market Impact: Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic tumors and is a leading cause of cancer-related deaths, underscoring the high unmet need.

Strong Clinical Progress and Future Outlook

The VIRAGE trial’s enrollment is expected to complete in the third quarter of 2024, with the potential to build on compelling clinical data. The FTD further validates VCN-01’s therapeutic potential and positions Theriva Biologics to deliver new treatment options to patients more rapidly.

Market Dynamics and Strategic Positioning

1. High Unmet Need: Pancreatic cancer is often diagnosed at advanced stages, limiting treatment options. VCN-01’s ability to target and degrade tumor stroma could significantly improve patient outcomes.

2. Expedited Development: FTD facilitates the development process, reducing the time to market and allowing Theriva Biologics to respond quickly to emerging data.

3. Investor Confidence: The FDA’s recognition of VCN-01’s potential can attract more investors, driving up demand and stock prices.

Theriva Biologics’ Diverse Pipeline

Beyond VCN-01, Theriva Biologics is advancing other promising candidates:

• SYN-004 (ribaxamase): Aims to prevent microbiome damage from IV beta-lactam antibiotics, reducing the incidence of acute graft-versus-host disease in transplant recipients.

• SYN-020: A recombinant oral enzyme targeting both GI and systemic diseases.

This diversified pipeline strengthens Theriva Biologics’ position in the biotech sector, making it an attractive investment opportunity.

Conclusion

Theriva Biologics (TOVX) is well-positioned for a significant stock price increase, driven by the FDA’s Fast Track Designation for VCN-01 and its promising potential in treating metastatic pancreatic cancer. The expedited development process, coupled with the high unmet need for effective PDAC treatments, sets the stage for a bullish outlook on TOVX. With a diversified pipeline and strategic advancements, Theriva Biologics is poised to make substantial strides in the biotech industry, making it a stock to watch closely.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Is a Silver Short Squeeze Brewing? Why iShares Silver Trust (SLV) Could Skyrocket

January 30, 2025

Could Southwest Airlines (LUV) Be the Next Meme Stock?

July 10, 2024

Why BWAQ Stock Price is Poised to Surge

May 29, 2024

Barnes & Noble Education (BNED) Stock: Potential Withdrawal from Greenhaven Deal Could Drive Prices Higher

May 23, 2024

Why Barnes & Noble (BNED) May Very Well Be The Next Big Meme Stock?

May 22, 2024

Is a Giant Short Squeeze Beginning in Barnes & Noble Education (BNED) Stock?

May 21, 2024

Leave A Reply Cancel Reply

Top Reviews
Editors Picks

7 days left: Founders and VCs save over $300 on all stage passes

March 24, 2025

AI chip startup Furiosaai reportedly rejecting $800 million acquisition offer from Meta

March 24, 2025

20 Hottest Open Source Startups of 2024

March 22, 2025

Andrill may build a weapons factory in the UK

March 21, 2025
About Us
About Us

Welcome to Tech Brunch, your go-to destination for cutting-edge insights, news, and analysis in the fields of Artificial Intelligence (AI), Cryptocurrency, Technology, and Startups. At Tech Brunch, we are passionate about exploring the latest trends, innovations, and developments shaping the future of these dynamic industries.

Our Picks

Humanity appoints national security experts to governing trusts

June 6, 2025

Italian lawmakers say Italy used spyware to target immigrant activists' mobile phones, but not for journalists

June 6, 2025

Trump Mask feud was perfect for X and jumped on the app store chart

June 6, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

© 2025 TechBrunch. Designed by TechBrunch.
  • Home
  • About Tech Brunch
  • Advertise with Tech Brunch
  • Contact us
  • DMCA Notice
  • Privacy Policy
  • Terms of Use

Type above and press Enter to search. Press Esc to cancel.